Related content

Targeting erythropoietin for chronic neurodegenerative diseases

By Chong Zhao Zhong  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 6, 2013-09 ,pp. : 707-720

Informa Healthcare

Access to resources Recommend Favorite

Targeting CNS Transporters for Treatment of Neurodegenerative Diseases

By  

Current Pharmaceutical Design, Vol. 20, Iss. 10, 2014-03 ,pp. : 1523-1533

Bentham Science Publishers

Access to resources Recommend Favorite

Selective targeting of synthetic antioxidants to mitochondria: towards a mitochondrial medicine for neurodegenerative diseases?

By Dessolin J.   Schuler M.   Quinart A.   De Giorgi F.   Ghosez L.   Ichas F.  

European Journal of Pharmacology, Vol. 447, Iss. 2, 2002-07 ,pp. : 155-161

Elsevier

Access to resources Recommend Favorite

Targeting ASK1 in ER stress-related neurodegenerative diseases

By Homma Kengo   Katagiri Kazumi   Nishitoh Hideki   Ichijo Hidenori  

Expert Opinion on Therapeutic Targets, Vol. 13, Iss. 6, 2009-06 ,pp. : 653-664

Informa Healthcare

Access to resources Recommend Favorite

Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases

By Bozdağ Pehlivan Sibel  

Pharmaceutical Research, Vol. 30, Iss. 10, 2013-10 ,pp. : 2499-2511

Springer Publishing Company

Access to resources Recommend Favorite